Alivus Life Sciences (ALVUS) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 revenue grew 12% YoY and 26.6% QoQ to INR 642 crores (₹6,418 Mn), driven by both GPL and non-GPL businesses, with generic business up 16.9% YoY and broad-based growth across India, Europe, ROW, and Japan.

• CDMO segment showed 25% QoQ growth, though YoY growth was subdued due to cyclical demand; fourth project commercialized, fifth project approval expected in FY26.

• Oncology pipeline progressing, with six products validated and six more in advanced development; commercial revenue from onco remains limited as products are in seeding phase.

• Rebranding to Alivus Life Sciences marks a strategic shift, emphasizing innovation, scalability, and geographic diversification.

• Free cash flow for 9MFY25 was INR 183.8 crores (₹1,838 Mn), with cash and equivalents at INR 499 crores (₹4,993 Mn) as of December 31, 2024.

Financial highlights

• Q3 gross margin at 55.6%-56%, EBITDA margin at 31.3% (up 90 bps YoY and 310 bps QoQ), and PAT at INR 137 crores (₹1,370 Mn) with a PAT margin of 21.3%.

• 9MFY25 revenue at INR 1,737 crores (₹17,373 Mn), gross profit INR 939 crores (gross margin 54.1%), EBITDA INR 509 crores (₹5,086 Mn, margin 29.3%), and PAT INR 344 crores (₹3,438 Mn, margin 19.8%).

• Volume growth for the quarter was 18%, with price erosion around 6%.

• EPS for Q3FY25 at ₹9.69 (basic/diluted EPS also reported as Rs. 11.18/11.14).

• R&D expenditure for nine months at INR 56 crores (3.2% of sales); Q3 R&D spend at INR 20 crores.

Outlook and guidance

• Optimistic outlook based on steady demand in India, Europe, Japan, and ROW; Americas expected to remain subdued for a few quarters.

• Significant future growth expected from new product launches, with half of revenue in 4-5 years projected to come from these.

• CapEx for next 3-4 years planned at INR 400-500 crores, including greenfield expansion in Solapur and a new R&D center.

• Fifth CDMO project expected to be commercialized by H1FY26; multiple new projects under discussion.

• Focus on new product launches, geographical expansion, and operational efficiencies.